PHARMACOLOGICAL EFFECTS OF ERIANIN AND ITS DERIVATIVES ON THE TUMOR MICROENVIRONMENT: CURRENT PERSPECTIVES
Keywords:
erianin, tumor microenvironment, cancer-associated fibroblasts, tumor-associated macrophages, angiogenesis, immunomodulation, oxidative stress, erianin derivatives.Abstract
Cancer development is determined not only by genetic and epigenetic alterations in tumor cells but also by complex interactions with the tumor microenvironment (TME). The TME consists of cancer-associated fibroblasts (CAFs), tumor-associated macrophages (TAMs), endothelial cells, immune cells, extracellular matrix, and various signaling molecules. These components play important roles in tumor proliferation, angiogenesis, invasion, metastasis, immune evasion, and the development of drug resistance [2,3]. Erianin is a naturally occurring dibenzyl compound isolated from plants belonging to the genus Dendrobium and has attracted considerable scientific interest in recent years due to its broad pharmacological properties, particularly its antitumor, antiangiogenic, immunomodulatory, and anti-inflammatory activities [1,2]. Available evidence indicates that erianin may affect several signaling pathways, including ROS/JNK, PI3K/AKT, JAK/STAT3, HIF-1α/PD-L1, mTOR, and Wnt/β-catenin [1,2]. In addition, experimental studies have demonstrated that erianin can inhibit angiogenesis, enhance the ability of macrophages to phagocytose tumor cells, and modulate the immune microenvironment [4–7]. The poor water solubility and limited bioavailability of erianin represent major factors restricting its pharmaceutical development and necessitate the development of novel derivatives and drug delivery systems [1,2]. This review analyzes the effects of erianin and its derivatives on the tumor microenvironment, their major molecular mechanisms, potential mechanisms of interaction with CAFs and TAMs, and future pharmacological perspectives.
References
1.Ma L, Li M, Zhang Y, Liu K. Recent advances of antitumor leading compound Erianin: Mechanisms of action and structural modification. European Journal of Medicinal Chemistry. 2023;261:115844. doi:10.1016/j.ejmech.2023.115844.
2.Wei X, et al. Research progress on the pharmacological mechanism, in vivo metabolism and structural modification of Erianin. Biomedicine & Pharmacotherapy. 2024;173:116295. doi:10.1016/j.biopha.2024.116295.
3.Cancer-associated fibroblasts: Origin, function, imaging, and therapeutic targeting. 2022.
4.Sun Y, Li G, Zhou Q, et al. Dual Targeting of Cell Growth and Phagocytosis by Erianin for Human Colorectal Cancer. Drug Design, Development and Therapy. 2020;14:3301–3313.
5.Erianin regulates programmed cell death ligand 1 expression and enhances cytotoxic T lymphocyte activity. 2020.
6.Erianin inhibits indoleamine 2,3-dioxygenase-induced tumor angiogenesis. 2017.
7.The anti-carcinogenesis properties of erianin in the modulation of oxidative stress-mediated apoptosis and immune response in liver cancer. 2019.
8.Erianin induces G2/M-phase arrest, apoptosis, and autophagy via the ROS/JNK signaling pathway in human osteosarcoma cells in vitro and in vivo. 2016.
9.Erianin suppresses proliferation and migration of cancer cells in a pyruvate carboxylase-dependent manner. Fitoterapia. 2022;157:105136.
10.Pandey P, et al. An Updated Review Deciphering the Inhibitory Potential of Erianin via Targeting Several Dysregulated Oncogenes in Several Human Carcinomas. Current Pharmaceutical Design. 2025.
11.Cancer-associated fibroblasts: Recent advances and therapeutic implications. Current Opinion in Cell Biology. 2026;98:102601.
12.Cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs); where do they stand in tumorigenesis and how they can change the face of cancer therapy? 2022.
13.The axis of tumor-associated macrophages, extracellular matrix proteins, and cancer-associated fibroblasts in oncogenesis. 2024.
14.The axis of tumor-associated macrophages, extracellular matrix proteins, and cancer-associated fibroblasts in oncogenesis. 2024.
15.In vivo and in vitro evaluation of erianin, a novel anti-angiogenic agent. 2004.
16.Zhou S, Qian S, Sun B, et al. Vascular normalization by erianin unleashes CAR-T immunotherapy in glioblastoma. Angiogenesis. 2026;29(2):18. doi:10.1007/s10456-026-10031-1.




United Kingdom
Germany
France
Uzbekistan
Türkiye
Kazakhstan
Kyrgyzstan
Turkmenistan
Azerbaijan
India
Republic of Korea
Japan
United States of America
Kosovo
Italy
Spain
Poland
Netherlands
Belgium
Sweden
Norway
Finland
Denmark
Switzerland
Austria
Czech Republic
Hungary
Romania
Bulgaria
Greece
Portugal